Talk:QIAGEN
 | The user below has a request that a significant addition or re-write be made to this article for which that user has an actual or apparent conflict of interest. The requested edits backlog is very low. There are currently 28 requests waiting for review. Please read the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies. |
- What I think should be changed (include citations):
First of all, I would like to make transparent that I'm working in QIAGEN's public relations department. As this implies a COI for this article, I suggest the changes I would like to make here instead of implementing them directly.
I would like to restore the "Acquisitions" section of QIAGEN's Wikipedia article after it had been deleted due to the lack of reliable sources. I have researched suitable sources that should match the Wikipedia guidelines. Please let me know if sources are not compliant with the guidelines so I can try to find alternatives.
I would like to add the following and have included the sources:
Acquisitions In 2004, QIAGEN acquired key assets of Molecular Staging, Inc.[1] Two years later, QIAGEN established its Asia regional headquarters in Shanghai. In 2007 sales reached US$649.8 million and the number of employees surpassed 2,600. QIAGEN acquired Digene for US$1.6 billion, furthering QIAGEN in molecular diagnostics by revenue and diagnostics for disease prevention.[2]
In 2009, QIAGEN began building its Personalized Healthcare business through the acquisition of DxS Ltd, in a deal valued at US$95 million[3] and it acquired SABiosciences Corp. in a deal valued at US$90 million.[4] At the end of 2009 QIAGEN surpassed the US$1 billion revenue mark and had over 3,500 employees. QIAGEN became one of the first companies to release a clinically verified diagnostic test for the detection of H1N1, more commonly known as Swine Flu.[5]
In 2010, QIAGEN acquired ESE GmbH, giving the company access to point of need testing devices for the application of molecular diagnostic tests without laboratory infrastructure.[6]
In 2011, QIAGEN acquired Ipsogen S.A. for US$101 million, adding to the company's product and IP portfolio in the blood cancer space.[7] QIAGEN also acquired Cellestis Limited for US$374 million, giving the company access to QuantiFERON technology for disease detection and prevention.[8] The company added two new offices in the Asia Pacific region in New Delhi, India and Taipei, Taiwan. The company announced a comprehensive restructuring program to focus on high-growth areas such as personalized medicine and business in emerging markets. The program includes workforce reduction and internal restructuring affecting approximately 10% of the company's 3,900 positions.[9]
In 2013, QIAGEN acquired Ingenuity Systems.[10] QIAGEN also acquired CLC bio, which offers bioinformatics analysis software.[11] In 2015, QIAGEN acquired AdnaGen's circulating tumor cell enrichment technology.[12] QIAGEN also acquired Enzymatic enzyme solutions.[13]
In March 2015, a management buyout of QIAGEN Marseille led to the creation of HalioDx.[14] In late 2015 the GeneReader NGS System was launched,[15] and the acquisition of Mo Bio Laboratories was completed.[16]
In 2016, QIAGEN acquired the Danish molecular diagnostics company Exiqon.[17]
In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets.[18]
In 2018, QIAGEN transferred its listing to New York Stock Exchange.[19] In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform.[20]
In 2019, QIAGEN announced the acquisition of Formulatrix assets to develop a digital PCR platform.[21] An additional acquisition of N-of-One, a privately held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data, to expand its QCI bioinformatics offerings.[22] In October 2019 QIAGEN entered into an agreement with Illumina granting QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina's diagnostic instruments.[23]
In September 2020 QIAGEN announced the acquisition of Michigan-based NeuMoDx Inc. to market two fully integrated systems for automated PCR.[24]
In May 2022, QIAGEN acquired the majority stake in BLIRT S.A., adding new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents.[25]
In January 2023, the business announced its intention to acquire Verogen for $150 million. This deal included acquiring GEDmatch.[26]
- Why it should be changed:
The acquisitions are an important part of QIAGEN's history and development and should therefore be part of the article.
Editorqiagen (talk) 11:42, 1 March 2024 (UTC)
References
- ^ Sheridan, Cormac. "Qiagen Pays $28.5M Cash For Molecular Staging Technology". bioworld.com. Retrieved 1 March 2024.
- ^ Flaherty, Michael; James, Steve. "Netherlands' Qiagen buying Digene for $1.6 bln". reuters.com. Reuters. Retrieved 1 March 2024.
- ^ Burger, Ludwig. "Qiagen raises capital, buys DxS". reuters.com. Retrieved 1 March 2024.
- ^ "Qiagen Acquires SABiosciences for $90M". genomeweb.com. Retrieved 1 March 2024.
- ^ "Qiagen Releases Influenza A/H1N1 Detection Kit for Research Purposes". genengnews.com. Retrieved 1 March 2024.
- ^ "QIAGEN Acquires ESE GmbH". bionity.com. Retrieved 1 March 2024.
- ^ "Qiagen übernimmt Mehrheit von Ipsogen". aerztezeitung.de. Springer Medizin Verlag GmbH. Retrieved 1 March 2024.
- ^ "Qiagen Completes Cellestis Acquisition". genomeweb.com. Retrieved 1 March 2024.
- ^ "Qiagen to Cut 8-10 Percent of Workforce in Restructuring". genomeweb.com. Retrieved 1 March 2024.
- ^ Burger, Ludwig. "Qiagen buys genetic data processor Ingenuity for $105 million". reuters.com. Retrieved 1 March 2024.
- ^ "QIAGEN Acquires CLC Bio". technologynetworks.com. Retrieved 1 March 2024.
- ^ "QIAGEN Expands Leadership in Liquid Biopsies". technologynetworks.com. Retrieved 1 March 2024.
- ^ Mullin, Emily. "Qiagen acquires Enzymatics, gains NGS partner ArcherDX". fiercebiotech.com. Questex LLC. Retrieved 1 March 2024.
- ^ Wasserman, Emily. "French cancer Dx company born after management buyout at Qiagen unit". fiercebiotech.com. Questex LLC. Retrieved 1 March 2024.
- ^ Karow, Julia. "Qiagen Launches GeneReader NGS System at AMP; Presents Performance Evaluation by Broad". genomeweb.com. Retrieved 1 March 2024.
- ^ "Qiagen Projects Q4, 2015 Shortfalls; Reports Acquisition of Mo Bio Labs". genomeweb.com. Retrieved 1 March 2024.
- ^ "Qiagen Completes Exiqon Tender Offer". genomeweb.com. Retrieved 1 March 2024.
- ^ Rodríguez Fernández, Clara. "Qiagen acquires Multi Omics Company to boost its Bioinformatics services". labiotech.eu. Labiotech UG. Retrieved 1 March 2024.
- ^ "Qiagen To Transfer U.S. Listing Of Global Shares To Nyse". reuters.com. Retrieved 1 March 2024.
- ^ Dale, Alex. "New Diagnostic Tests On the Way as Qiagen Snaps Up a Spanish Biotech". labiotech.eu. Labiotech UG. Retrieved 1 March 2024.
- ^ "FORMULATRIX® digital PCR technology to be acquired by QIAGEN". the-scientist.com. Retrieved 1 March 2024.
- ^ "QIAGEN To Acquire N-of-One, Inc. - Quick Facts". markets.businessinsider.com. Insider Inc. Retrieved 1 March 2024.
- ^ Anderson, Chris. "Illumina and Qiagen Enter 15-Year Diagnostics Partnership". insideprecisionmedicine.com. Mary Ann Liebert Inc., publishers. Retrieved 1 March 2024.
- ^ Taylor, Nick Paul. "Qiagen completes takeover of PCR automation player NeuMoDx for $248M". medtechdive.com. Industry Dive. Retrieved 1 March 2024.
- ^ "Qiagen Acquires Majority Stake in Enzyme Provider Blirt". genomeweb.com. Retrieved 1 March 2024.
- ^ "Qiagen acquires DNA-biometrics firm Verogen in $150 mln deal". reuters.com. Retrieved 1 March 2024.